Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating reaffirmed by equities researchers at Stifel Nicolaus in a research note issued to investors on Tuesday, July 11th. They currently have a GBX 71 ($0.92) price target on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ price objective points to a potential upside of 148.03% from the stock’s current price.
A number of other equities analysts have also commented on the stock. Peel Hunt reissued a “buy” rating and issued a GBX 68 ($0.89) price target on shares of Sinclair Pharma PLC in a research report on Tuesday, July 11th. N+1 Singer dropped their price target on shares of Sinclair Pharma PLC from GBX 42 ($0.55) to GBX 37 ($0.48) and set a “buy” rating on the stock in a research report on Wednesday, April 19th. Numis Securities Ltd reissued a “hold” rating and issued a GBX 35 ($0.46) price target on shares of Sinclair Pharma PLC in a research report on Tuesday, April 4th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a GBX 55 ($0.72) target price on shares of Sinclair Pharma PLC in a research report on Wednesday, March 22nd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of GBX 54 ($0.70).
Sinclair Pharma PLC (LON SPH) traded down 0.435% during mid-day trading on Tuesday, reaching GBX 28.625. 64,375 shares of the company traded hands. The stock has a 50-day moving average of GBX 30.10 and a 200 day moving average of GBX 31.75. The stock’s market capitalization is GBX 143.75 million. Sinclair Pharma PLC has a 52-week low of GBX 26.00 and a 52-week high of GBX 36.35.
COPYRIGHT VIOLATION WARNING: “Stifel Nicolaus Reaffirms Buy Rating for Sinclair Pharma PLC (LON:SPH)” was reported by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/08/08/sinclair-pharma-plc-lonsph-earns-buy-rating-from-stifel-nicolaus-updated-updated-updated.html.
Sinclair Pharma PLC Company Profile
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.